Rev Med Interne. 1993;14(10):1002. Unique Identifier : AIDSLINE
To assess the efficacy of pyrimethamine (Pyr) for primary prophylaxis of
cerebral toxoplasmosis (CT) in HIV patients (pts), 554 pts were
randomized in a double-blind, placebo-controlled trial (mean follow-up:
14 months). The intent-to-treat analysis found no significant difference
in the incidence of ct at 1 year: 12% (Pyr) versus 13% (Pcb) nor in
survival. Side-effects leading to stop the study drug were more frequent
in Pyr group, especially cutaneous rashes: 8% (Pyr) versus 2% (Pcb).
Double-Blind Method English Abstract Human HIV
Infections/*COMPLICATIONS *HIV-1 Placebos Pyrimethamine/*THERAPEUTIC
USE Toxoplasmosis, Cerebral/ETIOLOGY/*PREVENTION & CONTROL CLINICAL
TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL